Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting

International Journal of Clinical Practice

Volumn 58, Issue 2, 2004, Pages 201-206

  Olver, Ian N ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Antiemetic; Aprepitant; Chemotherapy; Nausea and vomiting

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; ANTIEMETIC AGENT; APOMORPHINE; APREPITANT; CISPLATIN; COPPER SULFATE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXAMETHASONE; DILTIAZEM; ERYTHROMYCIN; GRANISETRON; IPECAC; ISOENZYME; KETOCONAZOLE; LOPERAMIDE; METHYLPREDNISOLONE; MORPHINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NICOTINE; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; RIFAMPICIN; SEROTONIN ANTAGONIST; SUBSTANCE P; UNINDEXED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CROSS REACTION; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FEMALE; FERRET; FLUSHING; HEADACHE; HICCUP; HUMAN; MALE; MENSTRUATION DISORDER; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MORPHOLINES; SUBSTANCE P; TOMOGRAPHY, EMISSION-COMPUTED; VOMITING;

EID: 1842590585     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.0135.x     Document Type: Article

References (30)

1. Olver IN. Antiemetic study methodology: Recommendations for future studies. Oncology 1996; 53 (Suppl. 1): 96-101.
2. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68: 585-93.
3. Hesketh PJ, Van Belle S, Aappro M et al. Differential involvement of neurotransmitters through the time course of cisplatin induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003; 39: 1074-80.
4. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971-94.
5. Olver I, Paska W, Depierre A et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 1996; 7: 945-52.
6. Kris MG, Gralla RJ, Clark RA et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379-84.
7. Kris MG, Gralla RJ, Tyson LB et al. Controlling dallied vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 208-14.
8. Coates A, Abraham S, Kaye SB et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-8.
9. Boer-Dennert M, Wit R, Schmitz PJ et al. Patient perceptions of the side effects of chemotherapy: The influence of the 5-HT3 antagonists. Br J Cancer 1997; 76: 1055-61.
10. Osoba D, Zee B, Warr D et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997; 5: 307-13.
11. Grunberg SM, Hansen M, Deuson R et al. Incidence and impact of nausea/vomiting with modern antiemetics: Perception vs. reality. Proc Am Soc Clin Oncol 2002; 21: 250a.
12. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000; 60 (3): 533-46.
13. 1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002; 63 (Suppl. 11): 18-24.
14. 1 receptor antagonist GR203040. Br J Pharmacol 1995; 116: 3158-63.
15. 1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis. Neuropharmacology 2000; 39: 652-63.
16. McCrea JB, Majumbdar AK, Goldberg MR et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharm Ther 2003; 74: 17-24.
17. Blum RA, Majumdar AK, McCrea JB et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003; 25: 1407-19.
18. Kris MG, Cubeddu LX, Gralla RJ et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 1996; 78 (10): 2193-8.
19. Cocquyt V, Van Belle S, Reinhardt RR et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 835-42.
20. Van Belle S, Lichinitser MR, Navari RM et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: A randomized controlled trial. Cancer 2002; 94 (11): 3032-41.
21. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19 (6): 1759-67.
22. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999; 340 (3): 190-5.
23. 1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97 (9): 2290-300.
24. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97 (12): 3090-8.
25. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patient receiving high-dose cisplatin. The aprepitant protocol 052 study group. J Clin Oncol 2003; 21: 4112-9.
26. 1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 21: 4105-19.
27. Martin AR, Ma JG, Carides AD et al. The oral NK1 antagonist, aprepitant, was effective in maintaining patients' daily life activities in both male and female patients receiving highly emetogenic chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 750.
28. Bauwens G, Aapro MS, Pendergrass K et al. The oral NK1 receptor antagonist aprepitant is effective for the prevention of chemotherapy induced nausea and vomiting in elderly patients receiving high-dose cisplatin. Proc Am Soc Clin Oncol 2003; 22: 786.
29. Ma JG, Martin AR, Carides AD et al. The oral NK1 antagonist, aprepitant, is effective in reducing impact of chemotherapy-induced nausea and vomiting on daily life in both younger and older patients receiving highly emetogenic chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 785.
30. Aapro E, Selak M, Lichinitser D et al. Palonosetron (PALO) is more effective that ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): Results of a phase III trial. Proc Am Soc Clin Oncol 2003; 22: 726.